Applied Therapeutics to present 12-month clinical results for govorestat in rare disease treatment.

From GlobeNewswire: 2025-05-09 17:00:00

Applied Therapeutics, Inc. (Nasdaq: APLT) will present full 12-month clinical results from the INSPIRE Phase 3 trial of govorestat (AT-007) at the PNS 2025 Annual Meeting. The trial evaluated the effect of govorestat in patients with Sorbitol Dehydrogenase (SORD) Deficiency, a subtype of Charcot-Marie-Tooth (CMT) disease. The presentation will include new topline 18-month and 24-month data. Govorestat is a CNS penetrant Aldose Reductase Inhibitor being developed for the treatment of multiple rare diseases. It has received Orphan Drug Designations from both the EMA and FDA for various conditions. Applied Therapeutics is dedicated to developing novel drug candidates for rare diseases.



Read more at GlobeNewswire: Applied Therapeutics Announces Acceptance of Late-Breaking